Severe Obstructive Sleep Apnea Disrupts Vigilance-State-Dependent Metabolism

Int J Mol Sci. 2022 Nov 14;23(22):14052. doi: 10.3390/ijms232214052.

Abstract

The direct pathophysiological effects of obstructive sleep apnea (OSA) have been well described. However, the systemic and metabolic consequences of OSA are less well understood. The aim of this secondary analysis was to translate recent findings in healthy subjects on vigilance-state-dependent metabolism into the context of OSA patients and answer the question of how symptomatic OSA influences metabolism and whether these changes might explain metabolic and cardiovascular consequences of OSA. Patients with suspected OSA were assigned according to their oxygen desaturation index (ODI) and Epworth Sleepiness Scale (ESS) score into symptomatic OSA and controls. Vigilance-state-dependent breath metabolites assessed by high-resolution mass spectrometry were used to test for a difference in both groups. In total, 44 patients were eligible, of whom 18 (40.9%) were assigned to the symptomatic OSA group. Symptomatic OSA patients with a median [25%, 75% quartiles] ODI of 40.5 [35.0, 58.8] events/h and an ESS of 14.0 [11.2, 15.8] showed moderate to strong evidence for differences in 18 vigilance-state-dependent breath compounds compared to controls. These identified metabolites are part of major metabolic pathways in carbohydrate, amino acid, and lipid metabolism. Thus, beyond hypoxia per se, we hypothesize that disturbed sleep in OSA patients persists as disturbed sleep-dependent metabolite levels during daytime.

Keywords: breath analysis; metabolomics; mitochondria; obstructive sleep apnea; secondary electrospray ionization; sleep.

MeSH terms

  • Disorders of Excessive Somnolence* / complications
  • Humans
  • Oxygen
  • Sleep
  • Sleep Apnea, Obstructive* / complications
  • Wakefulness

Substances

  • Oxygen

Grants and funding

M.K. received funding from the Evi-Diethelm-Winteler-Foundation. S.B. received funding from the Swiss National Science Foundation and the Human Frontiers Science Program. M.K., S.B., and R.Z. received funding from the Zürich Exhalomics flagship project of the Zürich University Hospital and from the Heidi-Ras-Foundation. This work is part of the Zurich Exhalomics project under the umbrella of University Medicine Zurich/Hochschulmedizin Zürich.